Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IONQ Inc (IONQ) vs Medpace Holdings Inc (MEDP) Price & Performance

Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

IONQ Inc vs Medpace Holdings Inc — how do they compare? IONQ Inc trades at $45.02 (market cap $17.60B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: IONQ Inc and Medpace Holdings Inc are close in size by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals.

IONQMEDP
Market Cap
$17.60B$16.90B
Sector
TechnologyTechnology
52-Week High
$82.09$620.59
52-Week Low
$26.59$393.42
Enterprise Value
$15.53B$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IONQ Inc

IONQ trades at $45.20, up 6.28% today, with a bullish technical signal from moving averages and strong resistance near $46. The company reported Q2 2026 revenue growth of 287% to $80.1 million, though it missed EPS estimates. Analyst consensus is a Buy with a $73.33 price target, reflecting optimism on quantum computing leadership.

Outlook is growth-driven but high-risk; revenue is projected to double in 2026, yet net losses exceed $1.4 billion. Key risks include profitability timeline, cash burn, and competitive pressures. Upside hinges on execution of its quantum roadmap and defense contracts, but volatility persists.

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About IONQ Inc

IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.

Read more on IONQ

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP